JPWO2020023614A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020023614A5 JPWO2020023614A5 JP2021503813A JP2021503813A JPWO2020023614A5 JP WO2020023614 A5 JPWO2020023614 A5 JP WO2020023614A5 JP 2021503813 A JP2021503813 A JP 2021503813A JP 2021503813 A JP2021503813 A JP 2021503813A JP WO2020023614 A5 JPWO2020023614 A5 JP WO2020023614A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- pharmaceutical composition
- agents
- excipient
- inhaler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 100
- 239000003814 drug Substances 0.000 claims description 40
- 229940079593 drugs Drugs 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000003429 antifungal agent Substances 0.000 claims description 9
- 239000002105 nanoparticle Substances 0.000 claims description 9
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 7
- 229960004740 voriconazole Drugs 0.000 claims description 7
- 229940112141 Dry Powder Inhaler Drugs 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims description 4
- 229940071648 Metered Dose Inhaler Drugs 0.000 claims description 4
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims description 4
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229940035676 ANALGESICS Drugs 0.000 claims description 2
- 229940035674 ANESTHETICS Drugs 0.000 claims description 2
- 229940036592 ANTHELMINTICS Drugs 0.000 claims description 2
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 claims description 2
- 206010000496 Acne Diseases 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims description 2
- 229960001334 Corticosteroids Drugs 0.000 claims description 2
- 229940030606 DIURETICS Drugs 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 206010021639 Incontinence Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 230000003444 anaesthetic Effects 0.000 claims description 2
- 230000000202 analgesic Effects 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 230000000507 anthelmentic Effects 0.000 claims description 2
- 239000000921 anthelmintic agent Substances 0.000 claims description 2
- 239000004004 anti-anginal agent Substances 0.000 claims description 2
- 230000001396 anti-anti-diuretic Effects 0.000 claims description 2
- 230000000844 anti-bacterial Effects 0.000 claims description 2
- 230000002429 anti-coagulation Effects 0.000 claims description 2
- 230000001430 anti-depressive Effects 0.000 claims description 2
- 230000002605 anti-dotal Effects 0.000 claims description 2
- 239000000883 anti-obesity agent Substances 0.000 claims description 2
- 230000003262 anti-osteoporosis Effects 0.000 claims description 2
- 230000001028 anti-proliferant Effects 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 239000000924 antiasthmatic agent Substances 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 239000000729 antidote Substances 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 239000003430 antimalarial agent Substances 0.000 claims description 2
- 239000002282 antimigraine agent Substances 0.000 claims description 2
- 239000000939 antiparkinson agent Substances 0.000 claims description 2
- 239000003904 antiprotozoal agent Substances 0.000 claims description 2
- 239000003200 antithyroid agent Substances 0.000 claims description 2
- 239000003434 antitussive agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 239000002830 appetite depressant Substances 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 229940000425 combination drugs Drugs 0.000 claims description 2
- 239000003433 contraceptive agent Substances 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 230000002708 enhancing Effects 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000003419 expectorant Effects 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 239000004083 gastrointestinal agent Substances 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 239000005555 hypertensive agent Substances 0.000 claims description 2
- 230000000147 hypnotic Effects 0.000 claims description 2
- 239000003326 hypnotic agent Substances 0.000 claims description 2
- 230000001861 immunosuppresant Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 230000002601 intratumoral Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000001530 keratinolytic Effects 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 239000003149 muscarinic antagonist Substances 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- 230000000701 neuroleptic Effects 0.000 claims description 2
- 239000000014 opioid analgesic Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 230000001624 sedative Effects 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000000699 topical Effects 0.000 claims description 2
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims description 2
- 208000009856 Lung Disease Diseases 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 229940066493 Expectorants Drugs 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 102000000543 Histamine receptors Human genes 0.000 claims 1
- 108010002059 Histamine receptors Proteins 0.000 claims 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 claims 1
- 229940035363 MUSCLE RELAXANTS Drugs 0.000 claims 1
- 229940041033 Macrolides Drugs 0.000 claims 1
- 229940083876 Muscle relaxants FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940005483 OPIOID ANALGESICS Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003410 keratolytic agent Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 description 12
- 239000003960 organic solvent Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 150000003851 azoles Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
Description
[æ¬çºæ1001]
å»è¬çµæç©ã§ãã£ãŠãåèšå»è¬çµæç©ã¯ã
ïŒïŒ¡ïŒæ²»çè¬ãããã³
ïŒïŒ¢ïŒåèšå»è¬çµæç©ã®çŽ10ééïŒ æªæºãæ§æããã賊圢å€
ãå«ã¿ã
ããã§ãåèšå»è¬çµæç©ã¯ãåèšæ²»çè¬ã®ããç²åãå«ãããåéäœãšããŠè£œå€åãããŠãããåèšæ²»çè¬ã®åèšããç²åã®è¡šé¢ã¯ãåèšè³Šåœ¢å€ã®å¥åã®ãã¡ã€ã³ãå«ã¿ãåèšè³Šåœ¢å€ã®åèšå¥åã®ãã¡ã€ã³ã¯ãåèšæ²»çè¬ã®åèšããç²åéã®æ¥è§Šé¢ç©ãæžå°ãããã
åèšå»è¬çµæç©ã
[æ¬çºæ1002]
åèšæ²»çè¬ãçµæ¶åœ¢æ ã§ååšãããæ¬çºæ1001ã®å»è¬çµæç©ã
[æ¬çºæ1003]
åèšæ²»çè¬ãéæ¶è³ªåœ¢æ ã§ååšãããæ¬çºæ1001ã®å»è¬çµæç©ã
[æ¬çºæ1004]
åèšè³Šåœ¢å€ããåèšå»è¬çµæç©ã®çŽ9ïŒ ïœïŒïœïœçŽ1ïŒ ïœïŒïœãæ§æãããæ¬çºæ1001ïœ1003ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1005]
åèšè³Šåœ¢å€ããåèšå»è¬çµæç©ã®çŽ6ïŒ ïœïŒïœïœçŽ2ïŒ ïœïŒïœãæ§æãããæ¬çºæ1004ã®å»è¬çµæç©ã
[æ¬çºæ1006]
åèšè³Šåœ¢å€ããåèšå»è¬çµæç©ã®çŽ3ïŒ ïœïŒïœãæ§æãããæ¬çºæ1005ã®å»è¬çµæç©ã
[æ¬çºæ1007]
åèšè³Šåœ¢å€ããåèšå»è¬çµæç©ã®çŽ5ïŒ ïœïŒïœãæ§æãããæ¬çºæ1005ã®å»è¬çµæç©ã
[æ¬çºæ1008]
åèšè³Šåœ¢å€ã®åèšå¥åã®ãã¡ã€ã³ããåèšè¡šé¢äžã«ãããŠãåèšè³Šåœ¢å€ã®1ã€ä»¥äžã®äžé£ç¶ãã¡ã€ã³ãå«ããæ¬çºæ1001ïœ1007ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1009]
åèšè³Šåœ¢å€ã®åèšå¥åã®ãã¡ã€ã³ããåèšè³Šåœ¢å€ã®é£æ¥ããé£ç¶å±€ãå«ããæ¬çºæ1001ïœ1007ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1010]
åèšè³Šåœ¢å€ã氎溶æ§ã§ãããæ¬çºæ1001ïœ1009ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1011]
åèšè³Šåœ¢å€ãç³ã¢ã«ã³ãŒã«ã§ãããæ¬çºæ1001ïœ1010ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1012]
åèšè³Šåœ¢å€ããã³ãããŒã«ã§ãããæ¬çºæ1011ã®å»è¬çµæç©ã
[æ¬çºæ1013]
åèšè³Šåœ¢å€ããåèšå»è¬çµæç©äžã«ãããã¡ã€ã³ãšããŠååšãããæ¬çºæ1001ïœ1012ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1014]
åèšè³Šåœ¢å€ã®åèšãããã¡ã€ã³ããçŽ50ïœïœïœçŽ500ïœïœã®å€§ãããæãããæ¬çºæ1013ã®å»è¬çµæç©ã
[æ¬çºæ1015]
åèšè³Šåœ¢å€ãããã¡ã€ã³ã®å€§ããããçŽ100ïœïœïœçŽ200ïœïœã§ãããæ¬çºæ1014ã®å»è¬çµæç©ã
[æ¬çºæ1016]
çŽ1ïŒ5ïœçŽ7ïŒ5ÎŒïœã®ç©ºæ°åååŠç質éäžå€®ç²ååŸãæãããæ¬çºæ1001ïœ1015ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1017]
åèšç©ºæ°åååŠç質éäžå€®ç²ååŸãçŽ2ïŒ5ïœçŽ6ïŒ5ÎŒïœã§ãããæ¬çºæ1016ã®å»è¬çµæç©ã
[æ¬çºæ1018]
ã¯ãã¯ã¹è³Šåœ¢å€ãå«ãŸãªããæ¬çºæ1001ïœ1017ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1019]
çæ°Žæ§è³Šåœ¢å€ãå«ãŸãªããæ¬çºæ1018ã®å»è¬çµæç©ã
[æ¬çºæ1020]
åèšæ²»çè¬ããæçå€ãæçèå€ã粟ç¥ç¥çµçšå€ãäŸãã°é®çå€ãæèã¬ãã«ãå€åãããè¬å€ãäŸãã°éº»é è¬ãŸãã¯ç¡ç è¬ãéã¹ããã€ãæ§æççè¬ïŒïŒ®ïŒ³ïŒ¡ïŒ©ïŒ€ïŒ³ïŒãé§è«è¬ãããŒã¿ã¢ãŽãã¹ããæãããè¬ãæçå¿çè¬ãæäžæŽèè¬ãæåæ¯è¬ãæèè¬ãæè¯æ§åç«è ºè¥å€§è¬ãæååºè¬ãæãã€è¬ãæç³å°¿ç è¬ãé®åè¬ãæãŠãããè¬ãæç颚è¬ãæé«è¡å§è¬ãæççå€ãæãã©ãªã¢å€ãæçé çè¬ãæã ã¹ã«ãªã³å€ãæè «çè¬ãæè¥æºè¬ãæ骚ç²é¬çè¬ãæããŒãã³ãœã³ç è¬ãæå¢æ®å€ãæåè«è¬ãæç²ç¶è ºå€ãé®å³è¬ãæ尿倱çŠè¬ãæãŠã€ã«ã¹è¬ãæäžå®è¬ãé£æ¬²æå¶å€ãããŒã¿ãããã«ãŒãå¿èå€åå€ãååŠçæ³è¬ãèªç¥å¢åŒ·è¬ãé¿åŠè¬ãã³ã«ãã³ã¹ããã€ããïœïœïŒ2é»å®³å€ãå©å°¿è¬ãåèµ·äžå šæ¹åè¬ãå»ç°è¬ãèè žè¬ããã¹ã¿ãã³å容äœæ®æè¬ãå ç«æå¶è¬ãè§è³ªæº¶è§£è¬ãè質調ç¯è¬ããã€ã³ããªãšã³é»å®³å€ããã¯ãã©ã€ããçåŒç·©è¬ãç¥çµé®æè¬ãæ é€å€ããªããªã€ãé®çå€ããããã¢ãŒãŒé»å®³å€ãããã³é®éè¬ãå«ã矀ããéžæããããæ¬çºæ1001ïœ1019ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1021]
åèšæ²»çè¬ãæçèå€ã§ãããæ¬çºæ1020ã®å»è¬çµæç©ã
[æ¬çºæ1022]
åèšæçèå€ãã¢ãŸãŒã«ç³»æçèè¬ã§ãããæ¬çºæ1021ã®å»è¬çµæç©ã
[æ¬çºæ1023]
åèšã¢ãŸãŒã«ç³»æçèè¬ãããªã³ããŸãŒã«ã§ãããæ¬çºæ1022ã®å»è¬çµæç©ã
[æ¬çºæ1024]
1皮以äžã®è¿œå ã®è³Šåœ¢å€ãããã«å«ããæ¬çºæ1001ïœ1023ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1025]
1皮以äžã®è¿œå ã®æ²»çè¬ãããã«å«ããæ¬çºæ1001ïœ1024ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1026]
çµå£æäžãèèªå æäžãåèå æäžãé¢ç¯å æäžãé èå æäžãç®å æäžãç å·£å æäžãçèå æäžã錻è å æäžãçŒå æäžãå¿èå æäžãè ¹è å æäžãèžèå æäžãåç«è ºå æäžãçŽè žå æäžãé«è å æäžãæ°ç®¡å æäžãè «çå æäžãè垯å æäžãè£å æäžãéèå æäžãèè±å æäžãç¡åäœå æäžããªããœãŒã ã§ã®æäžãéšåçæäžãç²èæäžãéçµå£æäžãçŽè žæäžãçµèäžæäžãç®äžæäžãèäžæäžãå±ææäžãçµç®æäžãè£æäžãã¯ãªãŒã 圢æ ã§ã®æäžãè質çµæç©ã®åœ¢æ ã§ã®æäžãã«ããŒãã«ã«ããæäžãæŽæµã«ããæäžãæç¶æ³šå ¥ã«ããæäžãæ³šå ¥ã«ããæäžãåžå ¥ã«ããæäžã泚å°ã«ããæäžãå±æééã«ããæäžããŸãã¯å±æçæµã«ããæäžã®ããã«è£œå€åãããŠãããæ¬çºæ1001ïœ1025ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1027]
åžå ¥ã«ããæäžã®ããã«è£œå€åãããŠãããæ¬çºæ1026ã®å»è¬çµæç©ã
[æ¬çºæ1028]
åžå ¥åšã§äœ¿çšããããã«è£œå€åãããŠãããæ¬çºæ1001ïœ1027ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1029]
åèšåžå ¥åšããåºå®çšéã®çµã¿åããåžå ¥åšãååçšéã®ä¹Ÿç¥ç²æ«åžå ¥åšãè€æ°çšéã®ä¹Ÿç¥ç²æ«åžå ¥åšãè€æ°åäœçšéã®ä¹Ÿç¥ç²æ«åžå ¥åšãå®éåžå ¥åšããŸãã¯å å§å®éåžå ¥åšã§ãããæ¬çºæ1028ã®å»è¬çµæç©ã
[æ¬çºæ1030]
åèšåžå ¥åšãã«ãã»ã«ããŒã¹ã®åžå ¥åšã§ãããæ¬çºæ1029ã®å»è¬çµæç©ã
[æ¬çºæ1031]
åèšåžå ¥åšãäœæµæåžå ¥åšã§ãããæ¬çºæ1028ïœ1030ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1032]
åèšåžå ¥åšãé«æµæåžå ¥åšã§ãããæ¬çºæ1028ïœ1030ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1033]
åèšåžå ¥åšããçŽ10ïŒåïœçŽ150ïŒåã®æµéã§äœ¿çšããããæ¬çºæ1028ïœ1032ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1034]
åèšæµéãçŽ20ïŒåïœçŽ100ïŒåã§ãããæ¬çºæ1033ã®å»è¬çµæç©ã
[æ¬çºæ1035]
åèšåžå ¥åšã0ïŒ5ïœïŒ°ïœïœçŽ5ïœïŒ°ïœã®å§åå·®ãæãããæ¬çºæ1028ïœ1034ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1036]
åèšå§åå·®ã1ïœïŒ°ïœã2ïœïŒ°ïœããŸãã¯4ïœïŒ°ïœã§ãããæ¬çºæ1035ã®å»è¬çµæç©ã
[æ¬çºæ1037]
åèšåžå ¥åšãçŽ0ïŒ1ïœïœïœçŽ50ïœïœã®è² è·çšéãæãããæ¬çºæ1028ïœ1036ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1038]
åèšåžå ¥åšãçŽ0ïŒ1ïœïœïœçŽ10ïœïœã®è² è·çšéãæãããæ¬çºæ1037ã®å»è¬çµæç©ã
[æ¬çºæ1039]
åèšåžå ¥åšãçŽ5ïœïœïœçŽ50ïœïœã®è² è·çšéãæãããæ¬çºæ1037ã®å»è¬çµæç©ã
[æ¬çºæ1040]
åèšè² è·çšéãçŽ5ïœïœïœçŽ25ïœïœã§ãããæ¬çºæ1039ã®å»è¬çµæç©ã
[æ¬çºæ1041]
åžå ¥åšããé£ç¶çã«è² è·ããã1ã€ä»¥äžã®åäœçšéããã1ã€ã®ãŸãã¯äžé£ã®çšéãééããããã«æ§æãããŠãããæ¬çºæ1001ïœ1040ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1042]
åèšåžå ¥åšãã1ã€ã®åäœçšéãã1ã€ã®çšéãééããããã«æ§æãããŠãããæ¬çºæ1041ã®å»è¬çµæç©ã
[æ¬çºæ1043]
åèšåžå ¥åšãã1ã€ã®åäœçšéããäžé£ã®çšéãééããããã«æ§æãããŠãããæ¬çºæ1041ã®å»è¬çµæç©ã
[æ¬çºæ1044]
åèšåžå ¥åšããé£ç¶çã«è² è·ãããäžé£ã®ã«ãã»ã«ãããããã1ã€ã®çšéãééããããã«æ§æãããŠãããæ¬çºæ1041ã®å»è¬çµæç©ã
[æ¬çºæ1045]
åèšåžå ¥åšããé£ç¶çã«è² è·ãããäžé£ã®ã«ãã»ã«ããäžé£ã®çšéãééããããã«æ§æãããŠãããæ¬çºæ1041ã®å»è¬çµæç©ã
[æ¬çºæ1046]
ãã®å¿ èŠãããæ£è ã«ãããŠçŸæ£ãŸãã¯é害ãæ²»çãŸãã¯äºé²ããæ¹æ³ã§ãã£ãŠãåèšçŸæ£ãŸãã¯é害ãæ²»çããã®ã«æå¹ãªæ²»çè¬ãå«ããæ¬çºæ1001ïœ1045ã®ããããã®å»è¬çµæç©ã®æ²»çæå¹éããåèšæ£è ã«æäžããããšãå«ããåèšæ¹æ³ã
[æ¬çºæ1047]
åèšçŸæ£ãŸãã¯é害ãèºã«ããããã®ã§ãããæ¬çºæ1046ã®æ¹æ³ã
[æ¬çºæ1048]
åèšçŸæ£ãŸãã¯é害ãææçã§ãããæ¬çºæ1046ãŸãã¯æ¬çºæ1047ã®æ¹æ³ã
[æ¬çºæ1049]
åèšææçãçèã«ãããã®ã§ãããæ¬çºæ1046ïœ1048ã®ããããã®æ¹æ³ã
[æ¬çºæ1050]
åèšæ²»çè¬ãæçèå€ã§ãããæ¬çºæ1049ã®æ¹æ³ã
[æ¬çºæ1051]
åèšæ²»çè¬ãã¢ãŸãŒã«ç³»æçèå€ã§ãããæ¬çºæ1050ã®æ¹æ³ã
[æ¬çºæ1052]
åèšæ²»çè¬ãããªã³ããŸãŒã«ã§ãããæ¬çºæ1051ã®æ¹æ³ã
[æ¬çºæ1053]
å»è¬çµæç©ã調補ããæ¹æ³ã§ãã£ãŠã
ïŒïŒ¡ïŒæ²»çè¬ãšã10ïŒ ïœïŒïœæªæºã®éã§ååšãã賊圢å€ãšãã溶åªãšæ··åããŠãåé§äœæº¶æ¶²ã圢æããããšã
ïŒïŒ¢ïŒåèšæº¶åªãåçµãããã®ã«é©ãã枩床ã§ãåèšåé§äœæº¶æ¶²ãè¡šé¢ã«æ²çãããããšãããã³
ïŒïŒ£ïŒåèšæº¶åªãé€å»ããŠå»è¬çµæç©ãåŸãããš
ãå«ããåèšæ¹æ³ã
[æ¬çºæ1054]
åèšæº¶åªã2皮以äžã®æº¶åªã®æ··åç©ã§ãããæ¬çºæ1053ã®æ¹æ³ã
[æ¬çºæ1055]
溶åªã®åèšæ··åç©ãæ°Žãå«ããæ¬çºæ1054ã®æ¹æ³ã
[æ¬çºæ1056]
åèšæº¶åªãææ©æº¶åªã§ãããæ¬çºæ1055ã®æ¹æ³ã
[æ¬çºæ1057]
åèšææ©æº¶åªãã¢ã»ããããªã«ã§ãããæ¬çºæ1056ã®æ¹æ³ã
[æ¬çºæ1058]
åèšææ©æº¶åªã1ïŒ4ïŒãžãªããµã³ã§ãããæ¬çºæ1056ã®æ¹æ³ã
[æ¬çºæ1059]
åèšæº¶åªãæ°Žãšææ©æº¶åªãšã®æ··åç©ã§ãããæ¬çºæ1053ïœ1057ã®ããããã®æ¹æ³ã
[æ¬çºæ1060]
åèšæº¶åªãæ°Žãšã¢ã»ããããªã«ãšã®æ··åç©ã§ãããæ¬çºæ1059ã®æ¹æ³ã
[æ¬çºæ1061]
2皮以äžã®æº¶åªã®åèšæ··åç©ããçŽ10ïŒ ïœïŒïœïœçŽ90ïŒ ïœïŒïœã®ææ©æº¶åªãå«ããæ¬çºæ1053ïœ1060ã®ããããã®æ¹æ³ã
[æ¬çºæ1062]
åèšæ··åç©ããçŽ40ïŒ ïœïŒïœïœçŽ60ïŒ ïœïŒïœã®åèšææ©æº¶åªãå«ããæ¬çºæ1061ã®æ¹æ³ã
[æ¬çºæ1063]
åèšæ··åç©ããçŽ50ïŒ ïœïŒïœã®åèšææ©æº¶åªãå«ããæ¬çºæ1062ã®æ¹æ³ã
[æ¬çºæ1064]
åèšæ··åç©ããçŽ20ïŒ ïœïŒïœïœçŽ40ïŒ ïœïŒïœã®åèšææ©æº¶åªãå«ããæ¬çºæ1061ã®æ¹æ³ã
[æ¬çºæ1065]
åèšæ··åç©ããçŽ30ïŒ ïœïŒïœã®åèšææ©æº¶åªãå«ããæ¬çºæ1064ã®æ¹æ³ã
[æ¬çºæ1066]
åèšæ²»çè¬ããã³è³Šåœ¢å€ããåèšåé§äœæº¶æ¶²ã®10ïŒ ïœïŒïœæªæºãæ§æãããæ¬çºæ1053ïœ1065ã®ããããã®æ¹æ³ã
[æ¬çºæ1067]
åèšæ²»çè¬ããã³è³Šåœ¢å€ããåèšåé§äœæº¶æ¶²ã®çŽ0ïŒ5ïŒ ïœçŽ5ïŒ ïœïŒïœãæ§æãããæ¬çºæ1066ã®æ¹æ³ã
[æ¬çºæ1068]
åèšæ²»çè¬ããã³è³Šåœ¢å€ããåèšåé§äœæº¶æ¶²ã®çŽ1ïŒ ïœïŒïœãæ§æãããæ¬çºæ1067ã®æ¹æ³ã
[æ¬çºæ1069]
åèšæ²»çè¬ããã³è³Šåœ¢å€ããåèšåé§äœæº¶æ¶²ã®çŽ3ïŒ ïœïŒïœãæ§æãããæ¬çºæ1067ã®æ¹æ³ã
[æ¬çºæ1070]
åèšè¡šé¢ãå転ããŠãããæ¬çºæ1053ïœ1069ã®ããããã®æ¹æ³ã
[æ¬çºæ1071]
åèšæž©åºŠãçŽ0âïœçŽïŒ200âã§ãããæ¬çºæ1053ïœ1070ã®ããããã®æ¹æ³ã
[æ¬çºæ1072]
åèšæž©åºŠãçŽ0âïœçŽïŒ120âã§ãããæ¬çºæ1071ã®æ¹æ³ã
[æ¬çºæ1073]
åèšæž©åºŠãçŽïŒ50âïœçŽïŒ90âã§ãããæ¬çºæ1072ã®æ¹æ³ã
[æ¬çºæ1074]
åèšæž©åºŠãçŽïŒ60âã§ãããæ¬çºæ1073ã®æ¹æ³ã
[æ¬çºæ1075]
åèšæž©åºŠãçŽïŒ125âïœçŽïŒ175âã§ãããæ¬çºæ1072ã®æ¹æ³ã
[æ¬çºæ1076]
åèšæž©åºŠãçŽïŒ150âã§ãããæ¬çºæ1073ã®æ¹æ³ã
[æ¬çºæ1077]
åèšæº¶åªãæžå§äžã§é€å»ããããæ¬çºæ1053ïœ1076ã®ããããã®æ¹æ³ã
[æ¬çºæ1078]
åèšæº¶åªãåçµä¹Ÿç¥ã«ãã£ãŠé€å»ããããæ¬çºæ1077ã®æ¹æ³ã
[æ¬çºæ1079]
åèšåçµä¹Ÿç¥ããçŽïŒ20âïœçŽïŒ100âã®åçµä¹Ÿç¥æž©åºŠã§å®æœããããæ¬çºæ1078ã®æ¹æ³ã
[æ¬çºæ1080]
åèšåçµä¹Ÿç¥æž©åºŠãçŽïŒ40âã§ãããæ¬çºæ1079ã®æ¹æ³ã
[æ¬çºæ1081]
åèšæžå§ã250ïœïŒŽïœïœïœæªæºã§ãããæ¬çºæ1077ïœ1080ã®ããããã®æ¹æ³ã
[æ¬çºæ1082]
åèšæžå§ãçŽ100ïœïŒŽïœïœïœã§ãããæ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1083]
åèšå»è¬çµæç©ãæžå§äžã§å ç±ããããšãããã«å«ããæ¬çºæ1053ïœ1082ã®ããããã®æ¹æ³ã
[æ¬çºæ1084]
åèšå»è¬çµæç©ãçŽ0âïœçŽ30âã®æž©åºŠã«å ç±ããããæ¬çºæ1083ã®æ¹æ³ã
[æ¬çºæ1085]
åèšæž©åºŠã宀枩ä»è¿ãŸãã¯çŽ25âã§ãããæ¬çºæ1084ã®æ¹æ³ã
[æ¬çºæ1086]
åèšæžå§ã250ïœïŒŽïœïœïœæªæºã§ãããæ¬çºæ1083ïœ1085ã®ããããã®æ¹æ³ã
[æ¬çºæ1087]
åèšæžå§ãçŽ100ïœïŒŽïœïœïœã§ãããæ¬çºæ1086ã®æ¹æ³ã
[æ¬çºæ1088]
åèšæžå§ãåçµä¹Ÿç¥äžã®æžå§ãšåãã§ãããæ¬çºæ1083ïœ1087ã®ããããã®æ¹æ³ã
[æ¬çºæ1089]
æ¬çºæ1053ïœ1088ã®ããããã®æ¹æ³ã«åŸã£ãŠèª¿è£œããããå»è¬çµæç©ã
æ¬é瀺ã®ä»ã®ç®çãç¹åŸŽãããã³å©ç¹ã¯ã以äžã®è©³çŽ°ãªèª¬æããæããã«ãªãã§ããããããããªãããæ¬çºæã®ç²Ÿç¥ããã³ç¯å²å ã®æ§ã ãªå€æŽããã³ä¿®æ£ã¯ããã®è©³çŽ°ãªèª¬æããåœæ¥è ã«ã¯æããã«ãªãã§ãããããããã®è©³çŽ°ãªèª¬æããã³å ·äœäŸã¯ãæ¬çºæã®ç¹å®ã®å®æœåœ¢æ ã瀺ãããäŸç€ºã®ã¿ãç®çãšããŠäžããããããšãç解ããããã
å»è¬çµæç©ã§ãã£ãŠãåèšå»è¬çµæç©ã¯ã
ïŒïŒ¡ïŒæ²»çè¬ãããã³
ïŒïŒ¢ïŒåèšå»è¬çµæç©ã®çŽ10ééïŒ æªæºãæ§æããã賊圢å€
ãå«ã¿ã
ããã§ãåèšå»è¬çµæç©ã¯ãåèšæ²»çè¬ã®ããç²åãå«ãããåéäœãšããŠè£œå€åãããŠãããåèšæ²»çè¬ã®åèšããç²åã®è¡šé¢ã¯ãåèšè³Šåœ¢å€ã®å¥åã®ãã¡ã€ã³ãå«ã¿ãåèšè³Šåœ¢å€ã®åèšå¥åã®ãã¡ã€ã³ã¯ãåèšæ²»çè¬ã®åèšããç²åéã®æ¥è§Šé¢ç©ãæžå°ãããã
åèšå»è¬çµæç©ã
[æ¬çºæ1002]
åèšæ²»çè¬ãçµæ¶åœ¢æ ã§ååšãããæ¬çºæ1001ã®å»è¬çµæç©ã
[æ¬çºæ1003]
åèšæ²»çè¬ãéæ¶è³ªåœ¢æ ã§ååšãããæ¬çºæ1001ã®å»è¬çµæç©ã
[æ¬çºæ1004]
åèšè³Šåœ¢å€ããåèšå»è¬çµæç©ã®çŽ9ïŒ ïœïŒïœïœçŽ1ïŒ ïœïŒïœãæ§æãããæ¬çºæ1001ïœ1003ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1005]
åèšè³Šåœ¢å€ããåèšå»è¬çµæç©ã®çŽ6ïŒ ïœïŒïœïœçŽ2ïŒ ïœïŒïœãæ§æãããæ¬çºæ1004ã®å»è¬çµæç©ã
[æ¬çºæ1006]
åèšè³Šåœ¢å€ããåèšå»è¬çµæç©ã®çŽ3ïŒ ïœïŒïœãæ§æãããæ¬çºæ1005ã®å»è¬çµæç©ã
[æ¬çºæ1007]
åèšè³Šåœ¢å€ããåèšå»è¬çµæç©ã®çŽ5ïŒ ïœïŒïœãæ§æãããæ¬çºæ1005ã®å»è¬çµæç©ã
[æ¬çºæ1008]
åèšè³Šåœ¢å€ã®åèšå¥åã®ãã¡ã€ã³ããåèšè¡šé¢äžã«ãããŠãåèšè³Šåœ¢å€ã®1ã€ä»¥äžã®äžé£ç¶ãã¡ã€ã³ãå«ããæ¬çºæ1001ïœ1007ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1009]
åèšè³Šåœ¢å€ã®åèšå¥åã®ãã¡ã€ã³ããåèšè³Šåœ¢å€ã®é£æ¥ããé£ç¶å±€ãå«ããæ¬çºæ1001ïœ1007ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1010]
åèšè³Šåœ¢å€ã氎溶æ§ã§ãããæ¬çºæ1001ïœ1009ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1011]
åèšè³Šåœ¢å€ãç³ã¢ã«ã³ãŒã«ã§ãããæ¬çºæ1001ïœ1010ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1012]
åèšè³Šåœ¢å€ããã³ãããŒã«ã§ãããæ¬çºæ1011ã®å»è¬çµæç©ã
[æ¬çºæ1013]
åèšè³Šåœ¢å€ããåèšå»è¬çµæç©äžã«ãããã¡ã€ã³ãšããŠååšãããæ¬çºæ1001ïœ1012ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1014]
åèšè³Šåœ¢å€ã®åèšãããã¡ã€ã³ããçŽ50ïœïœïœçŽ500ïœïœã®å€§ãããæãããæ¬çºæ1013ã®å»è¬çµæç©ã
[æ¬çºæ1015]
åèšè³Šåœ¢å€ãããã¡ã€ã³ã®å€§ããããçŽ100ïœïœïœçŽ200ïœïœã§ãããæ¬çºæ1014ã®å»è¬çµæç©ã
[æ¬çºæ1016]
çŽ1ïŒ5ïœçŽ7ïŒ5ÎŒïœã®ç©ºæ°åååŠç質éäžå€®ç²ååŸãæãããæ¬çºæ1001ïœ1015ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1017]
åèšç©ºæ°åååŠç質éäžå€®ç²ååŸãçŽ2ïŒ5ïœçŽ6ïŒ5ÎŒïœã§ãããæ¬çºæ1016ã®å»è¬çµæç©ã
[æ¬çºæ1018]
ã¯ãã¯ã¹è³Šåœ¢å€ãå«ãŸãªããæ¬çºæ1001ïœ1017ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1019]
çæ°Žæ§è³Šåœ¢å€ãå«ãŸãªããæ¬çºæ1018ã®å»è¬çµæç©ã
[æ¬çºæ1020]
åèšæ²»çè¬ããæçå€ãæçèå€ã粟ç¥ç¥çµçšå€ãäŸãã°é®çå€ãæèã¬ãã«ãå€åãããè¬å€ãäŸãã°éº»é è¬ãŸãã¯ç¡ç è¬ãéã¹ããã€ãæ§æççè¬ïŒïŒ®ïŒ³ïŒ¡ïŒ©ïŒ€ïŒ³ïŒãé§è«è¬ãããŒã¿ã¢ãŽãã¹ããæãããè¬ãæçå¿çè¬ãæäžæŽèè¬ãæåæ¯è¬ãæèè¬ãæè¯æ§åç«è ºè¥å€§è¬ãæååºè¬ãæãã€è¬ãæç³å°¿ç è¬ãé®åè¬ãæãŠãããè¬ãæç颚è¬ãæé«è¡å§è¬ãæççå€ãæãã©ãªã¢å€ãæçé çè¬ãæã ã¹ã«ãªã³å€ãæè «çè¬ãæè¥æºè¬ãæ骚ç²é¬çè¬ãæããŒãã³ãœã³ç è¬ãæå¢æ®å€ãæåè«è¬ãæç²ç¶è ºå€ãé®å³è¬ãæ尿倱çŠè¬ãæãŠã€ã«ã¹è¬ãæäžå®è¬ãé£æ¬²æå¶å€ãããŒã¿ãããã«ãŒãå¿èå€åå€ãååŠçæ³è¬ãèªç¥å¢åŒ·è¬ãé¿åŠè¬ãã³ã«ãã³ã¹ããã€ããïœïœïŒ2é»å®³å€ãå©å°¿è¬ãåèµ·äžå šæ¹åè¬ãå»ç°è¬ãèè žè¬ããã¹ã¿ãã³å容äœæ®æè¬ãå ç«æå¶è¬ãè§è³ªæº¶è§£è¬ãè質調ç¯è¬ããã€ã³ããªãšã³é»å®³å€ããã¯ãã©ã€ããçåŒç·©è¬ãç¥çµé®æè¬ãæ é€å€ããªããªã€ãé®çå€ããããã¢ãŒãŒé»å®³å€ãããã³é®éè¬ãå«ã矀ããéžæããããæ¬çºæ1001ïœ1019ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1021]
åèšæ²»çè¬ãæçèå€ã§ãããæ¬çºæ1020ã®å»è¬çµæç©ã
[æ¬çºæ1022]
åèšæçèå€ãã¢ãŸãŒã«ç³»æçèè¬ã§ãããæ¬çºæ1021ã®å»è¬çµæç©ã
[æ¬çºæ1023]
åèšã¢ãŸãŒã«ç³»æçèè¬ãããªã³ããŸãŒã«ã§ãããæ¬çºæ1022ã®å»è¬çµæç©ã
[æ¬çºæ1024]
1皮以äžã®è¿œå ã®è³Šåœ¢å€ãããã«å«ããæ¬çºæ1001ïœ1023ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1025]
1皮以äžã®è¿œå ã®æ²»çè¬ãããã«å«ããæ¬çºæ1001ïœ1024ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1026]
çµå£æäžãèèªå æäžãåèå æäžãé¢ç¯å æäžãé èå æäžãç®å æäžãç å·£å æäžãçèå æäžã錻è å æäžãçŒå æäžãå¿èå æäžãè ¹è å æäžãèžèå æäžãåç«è ºå æäžãçŽè žå æäžãé«è å æäžãæ°ç®¡å æäžãè «çå æäžãè垯å æäžãè£å æäžãéèå æäžãèè±å æäžãç¡åäœå æäžããªããœãŒã ã§ã®æäžãéšåçæäžãç²èæäžãéçµå£æäžãçŽè žæäžãçµèäžæäžãç®äžæäžãèäžæäžãå±ææäžãçµç®æäžãè£æäžãã¯ãªãŒã 圢æ ã§ã®æäžãè質çµæç©ã®åœ¢æ ã§ã®æäžãã«ããŒãã«ã«ããæäžãæŽæµã«ããæäžãæç¶æ³šå ¥ã«ããæäžãæ³šå ¥ã«ããæäžãåžå ¥ã«ããæäžã泚å°ã«ããæäžãå±æééã«ããæäžããŸãã¯å±æçæµã«ããæäžã®ããã«è£œå€åãããŠãããæ¬çºæ1001ïœ1025ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1027]
åžå ¥ã«ããæäžã®ããã«è£œå€åãããŠãããæ¬çºæ1026ã®å»è¬çµæç©ã
[æ¬çºæ1028]
åžå ¥åšã§äœ¿çšããããã«è£œå€åãããŠãããæ¬çºæ1001ïœ1027ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1029]
åèšåžå ¥åšããåºå®çšéã®çµã¿åããåžå ¥åšãååçšéã®ä¹Ÿç¥ç²æ«åžå ¥åšãè€æ°çšéã®ä¹Ÿç¥ç²æ«åžå ¥åšãè€æ°åäœçšéã®ä¹Ÿç¥ç²æ«åžå ¥åšãå®éåžå ¥åšããŸãã¯å å§å®éåžå ¥åšã§ãããæ¬çºæ1028ã®å»è¬çµæç©ã
[æ¬çºæ1030]
åèšåžå ¥åšãã«ãã»ã«ããŒã¹ã®åžå ¥åšã§ãããæ¬çºæ1029ã®å»è¬çµæç©ã
[æ¬çºæ1031]
åèšåžå ¥åšãäœæµæåžå ¥åšã§ãããæ¬çºæ1028ïœ1030ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1032]
åèšåžå ¥åšãé«æµæåžå ¥åšã§ãããæ¬çºæ1028ïœ1030ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1033]
åèšåžå ¥åšããçŽ10ïŒåïœçŽ150ïŒåã®æµéã§äœ¿çšããããæ¬çºæ1028ïœ1032ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1034]
åèšæµéãçŽ20ïŒåïœçŽ100ïŒåã§ãããæ¬çºæ1033ã®å»è¬çµæç©ã
[æ¬çºæ1035]
åèšåžå ¥åšã0ïŒ5ïœïŒ°ïœïœçŽ5ïœïŒ°ïœã®å§åå·®ãæãããæ¬çºæ1028ïœ1034ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1036]
åèšå§åå·®ã1ïœïŒ°ïœã2ïœïŒ°ïœããŸãã¯4ïœïŒ°ïœã§ãããæ¬çºæ1035ã®å»è¬çµæç©ã
[æ¬çºæ1037]
åèšåžå ¥åšãçŽ0ïŒ1ïœïœïœçŽ50ïœïœã®è² è·çšéãæãããæ¬çºæ1028ïœ1036ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1038]
åèšåžå ¥åšãçŽ0ïŒ1ïœïœïœçŽ10ïœïœã®è² è·çšéãæãããæ¬çºæ1037ã®å»è¬çµæç©ã
[æ¬çºæ1039]
åèšåžå ¥åšãçŽ5ïœïœïœçŽ50ïœïœã®è² è·çšéãæãããæ¬çºæ1037ã®å»è¬çµæç©ã
[æ¬çºæ1040]
åèšè² è·çšéãçŽ5ïœïœïœçŽ25ïœïœã§ãããæ¬çºæ1039ã®å»è¬çµæç©ã
[æ¬çºæ1041]
åžå ¥åšããé£ç¶çã«è² è·ããã1ã€ä»¥äžã®åäœçšéããã1ã€ã®ãŸãã¯äžé£ã®çšéãééããããã«æ§æãããŠãããæ¬çºæ1001ïœ1040ã®ããããã®å»è¬çµæç©ã
[æ¬çºæ1042]
åèšåžå ¥åšãã1ã€ã®åäœçšéãã1ã€ã®çšéãééããããã«æ§æãããŠãããæ¬çºæ1041ã®å»è¬çµæç©ã
[æ¬çºæ1043]
åèšåžå ¥åšãã1ã€ã®åäœçšéããäžé£ã®çšéãééããããã«æ§æãããŠãããæ¬çºæ1041ã®å»è¬çµæç©ã
[æ¬çºæ1044]
åèšåžå ¥åšããé£ç¶çã«è² è·ãããäžé£ã®ã«ãã»ã«ãããããã1ã€ã®çšéãééããããã«æ§æãããŠãããæ¬çºæ1041ã®å»è¬çµæç©ã
[æ¬çºæ1045]
åèšåžå ¥åšããé£ç¶çã«è² è·ãããäžé£ã®ã«ãã»ã«ããäžé£ã®çšéãééããããã«æ§æãããŠãããæ¬çºæ1041ã®å»è¬çµæç©ã
[æ¬çºæ1046]
ãã®å¿ èŠãããæ£è ã«ãããŠçŸæ£ãŸãã¯é害ãæ²»çãŸãã¯äºé²ããæ¹æ³ã§ãã£ãŠãåèšçŸæ£ãŸãã¯é害ãæ²»çããã®ã«æå¹ãªæ²»çè¬ãå«ããæ¬çºæ1001ïœ1045ã®ããããã®å»è¬çµæç©ã®æ²»çæå¹éããåèšæ£è ã«æäžããããšãå«ããåèšæ¹æ³ã
[æ¬çºæ1047]
åèšçŸæ£ãŸãã¯é害ãèºã«ããããã®ã§ãããæ¬çºæ1046ã®æ¹æ³ã
[æ¬çºæ1048]
åèšçŸæ£ãŸãã¯é害ãææçã§ãããæ¬çºæ1046ãŸãã¯æ¬çºæ1047ã®æ¹æ³ã
[æ¬çºæ1049]
åèšææçãçèã«ãããã®ã§ãããæ¬çºæ1046ïœ1048ã®ããããã®æ¹æ³ã
[æ¬çºæ1050]
åèšæ²»çè¬ãæçèå€ã§ãããæ¬çºæ1049ã®æ¹æ³ã
[æ¬çºæ1051]
åèšæ²»çè¬ãã¢ãŸãŒã«ç³»æçèå€ã§ãããæ¬çºæ1050ã®æ¹æ³ã
[æ¬çºæ1052]
åèšæ²»çè¬ãããªã³ããŸãŒã«ã§ãããæ¬çºæ1051ã®æ¹æ³ã
[æ¬çºæ1053]
å»è¬çµæç©ã調補ããæ¹æ³ã§ãã£ãŠã
ïŒïŒ¡ïŒæ²»çè¬ãšã10ïŒ ïœïŒïœæªæºã®éã§ååšãã賊圢å€ãšãã溶åªãšæ··åããŠãåé§äœæº¶æ¶²ã圢æããããšã
ïŒïŒ¢ïŒåèšæº¶åªãåçµãããã®ã«é©ãã枩床ã§ãåèšåé§äœæº¶æ¶²ãè¡šé¢ã«æ²çãããããšãããã³
ïŒïŒ£ïŒåèšæº¶åªãé€å»ããŠå»è¬çµæç©ãåŸãããš
ãå«ããåèšæ¹æ³ã
[æ¬çºæ1054]
åèšæº¶åªã2皮以äžã®æº¶åªã®æ··åç©ã§ãããæ¬çºæ1053ã®æ¹æ³ã
[æ¬çºæ1055]
溶åªã®åèšæ··åç©ãæ°Žãå«ããæ¬çºæ1054ã®æ¹æ³ã
[æ¬çºæ1056]
åèšæº¶åªãææ©æº¶åªã§ãããæ¬çºæ1055ã®æ¹æ³ã
[æ¬çºæ1057]
åèšææ©æº¶åªãã¢ã»ããããªã«ã§ãããæ¬çºæ1056ã®æ¹æ³ã
[æ¬çºæ1058]
åèšææ©æº¶åªã1ïŒ4ïŒãžãªããµã³ã§ãããæ¬çºæ1056ã®æ¹æ³ã
[æ¬çºæ1059]
åèšæº¶åªãæ°Žãšææ©æº¶åªãšã®æ··åç©ã§ãããæ¬çºæ1053ïœ1057ã®ããããã®æ¹æ³ã
[æ¬çºæ1060]
åèšæº¶åªãæ°Žãšã¢ã»ããããªã«ãšã®æ··åç©ã§ãããæ¬çºæ1059ã®æ¹æ³ã
[æ¬çºæ1061]
2皮以äžã®æº¶åªã®åèšæ··åç©ããçŽ10ïŒ ïœïŒïœïœçŽ90ïŒ ïœïŒïœã®ææ©æº¶åªãå«ããæ¬çºæ1053ïœ1060ã®ããããã®æ¹æ³ã
[æ¬çºæ1062]
åèšæ··åç©ããçŽ40ïŒ ïœïŒïœïœçŽ60ïŒ ïœïŒïœã®åèšææ©æº¶åªãå«ããæ¬çºæ1061ã®æ¹æ³ã
[æ¬çºæ1063]
åèšæ··åç©ããçŽ50ïŒ ïœïŒïœã®åèšææ©æº¶åªãå«ããæ¬çºæ1062ã®æ¹æ³ã
[æ¬çºæ1064]
åèšæ··åç©ããçŽ20ïŒ ïœïŒïœïœçŽ40ïŒ ïœïŒïœã®åèšææ©æº¶åªãå«ããæ¬çºæ1061ã®æ¹æ³ã
[æ¬çºæ1065]
åèšæ··åç©ããçŽ30ïŒ ïœïŒïœã®åèšææ©æº¶åªãå«ããæ¬çºæ1064ã®æ¹æ³ã
[æ¬çºæ1066]
åèšæ²»çè¬ããã³è³Šåœ¢å€ããåèšåé§äœæº¶æ¶²ã®10ïŒ ïœïŒïœæªæºãæ§æãããæ¬çºæ1053ïœ1065ã®ããããã®æ¹æ³ã
[æ¬çºæ1067]
åèšæ²»çè¬ããã³è³Šåœ¢å€ããåèšåé§äœæº¶æ¶²ã®çŽ0ïŒ5ïŒ ïœçŽ5ïŒ ïœïŒïœãæ§æãããæ¬çºæ1066ã®æ¹æ³ã
[æ¬çºæ1068]
åèšæ²»çè¬ããã³è³Šåœ¢å€ããåèšåé§äœæº¶æ¶²ã®çŽ1ïŒ ïœïŒïœãæ§æãããæ¬çºæ1067ã®æ¹æ³ã
[æ¬çºæ1069]
åèšæ²»çè¬ããã³è³Šåœ¢å€ããåèšåé§äœæº¶æ¶²ã®çŽ3ïŒ ïœïŒïœãæ§æãããæ¬çºæ1067ã®æ¹æ³ã
[æ¬çºæ1070]
åèšè¡šé¢ãå転ããŠãããæ¬çºæ1053ïœ1069ã®ããããã®æ¹æ³ã
[æ¬çºæ1071]
åèšæž©åºŠãçŽ0âïœçŽïŒ200âã§ãããæ¬çºæ1053ïœ1070ã®ããããã®æ¹æ³ã
[æ¬çºæ1072]
åèšæž©åºŠãçŽ0âïœçŽïŒ120âã§ãããæ¬çºæ1071ã®æ¹æ³ã
[æ¬çºæ1073]
åèšæž©åºŠãçŽïŒ50âïœçŽïŒ90âã§ãããæ¬çºæ1072ã®æ¹æ³ã
[æ¬çºæ1074]
åèšæž©åºŠãçŽïŒ60âã§ãããæ¬çºæ1073ã®æ¹æ³ã
[æ¬çºæ1075]
åèšæž©åºŠãçŽïŒ125âïœçŽïŒ175âã§ãããæ¬çºæ1072ã®æ¹æ³ã
[æ¬çºæ1076]
åèšæž©åºŠãçŽïŒ150âã§ãããæ¬çºæ1073ã®æ¹æ³ã
[æ¬çºæ1077]
åèšæº¶åªãæžå§äžã§é€å»ããããæ¬çºæ1053ïœ1076ã®ããããã®æ¹æ³ã
[æ¬çºæ1078]
åèšæº¶åªãåçµä¹Ÿç¥ã«ãã£ãŠé€å»ããããæ¬çºæ1077ã®æ¹æ³ã
[æ¬çºæ1079]
åèšåçµä¹Ÿç¥ããçŽïŒ20âïœçŽïŒ100âã®åçµä¹Ÿç¥æž©åºŠã§å®æœããããæ¬çºæ1078ã®æ¹æ³ã
[æ¬çºæ1080]
åèšåçµä¹Ÿç¥æž©åºŠãçŽïŒ40âã§ãããæ¬çºæ1079ã®æ¹æ³ã
[æ¬çºæ1081]
åèšæžå§ã250ïœïŒŽïœïœïœæªæºã§ãããæ¬çºæ1077ïœ1080ã®ããããã®æ¹æ³ã
[æ¬çºæ1082]
åèšæžå§ãçŽ100ïœïŒŽïœïœïœã§ãããæ¬çºæ1081ã®æ¹æ³ã
[æ¬çºæ1083]
åèšå»è¬çµæç©ãæžå§äžã§å ç±ããããšãããã«å«ããæ¬çºæ1053ïœ1082ã®ããããã®æ¹æ³ã
[æ¬çºæ1084]
åèšå»è¬çµæç©ãçŽ0âïœçŽ30âã®æž©åºŠã«å ç±ããããæ¬çºæ1083ã®æ¹æ³ã
[æ¬çºæ1085]
åèšæž©åºŠã宀枩ä»è¿ãŸãã¯çŽ25âã§ãããæ¬çºæ1084ã®æ¹æ³ã
[æ¬çºæ1086]
åèšæžå§ã250ïœïŒŽïœïœïœæªæºã§ãããæ¬çºæ1083ïœ1085ã®ããããã®æ¹æ³ã
[æ¬çºæ1087]
åèšæžå§ãçŽ100ïœïŒŽïœïœïœã§ãããæ¬çºæ1086ã®æ¹æ³ã
[æ¬çºæ1088]
åèšæžå§ãåçµä¹Ÿç¥äžã®æžå§ãšåãã§ãããæ¬çºæ1083ïœ1087ã®ããããã®æ¹æ³ã
[æ¬çºæ1089]
æ¬çºæ1053ïœ1088ã®ããããã®æ¹æ³ã«åŸã£ãŠèª¿è£œããããå»è¬çµæç©ã
æ¬é瀺ã®ä»ã®ç®çãç¹åŸŽãããã³å©ç¹ã¯ã以äžã®è©³çŽ°ãªèª¬æããæããã«ãªãã§ããããããããªãããæ¬çºæã®ç²Ÿç¥ããã³ç¯å²å ã®æ§ã ãªå€æŽããã³ä¿®æ£ã¯ããã®è©³çŽ°ãªèª¬æããåœæ¥è ã«ã¯æããã«ãªãã§ãããããããã®è©³çŽ°ãªèª¬æããã³å ·äœäŸã¯ãæ¬çºæã®ç¹å®ã®å®æœåœ¢æ ã瀺ãããäŸç€ºã®ã¿ãç®çãšããŠäžããããããšãç解ããããã
Claims (32)
- å»è¬çµæç©ã§ãã£ãŠãåèšå»è¬çµæç©ã¯ã
ïŒïŒ¡ïŒæ²»çè¬ãããã³
ïŒïŒ¢ïŒåèšå»è¬çµæç©ã®çŽïŒïŒééïŒ æªæºãæ§æããã賊圢å€
ãå«ã¿ã
ããã§ãåèšå»è¬çµæç©ã¯ãåèšæ²»çè¬ã®ããç²åãå«ãããåéäœãšããŠè£œå€åãããŠãããåèšæ²»çè¬ã®åèšããç²åã®è¡šé¢ã¯ãåèšè³Šåœ¢å€ã®å¥åã®ãã¡ã€ã³ãå«ã¿ãåèšè³Šåœ¢å€ã®åèšå¥åã®ãã¡ã€ã³ã¯ãåèšæ²»çè¬ã®åèšããç²åéã®æ¥è§Šé¢ç©ãæžå°ãããã
åèšå»è¬çµæç©ã - åèšæ²»çè¬ãçµæ¶åœ¢æ ã§ååšãããè«æ±é ïŒã«èšèŒã®å»è¬çµæç©ã
- åèšæ²»çè¬ãéæ¶è³ªåœ¢æ ã§ååšãããè«æ±é ïŒã«èšèŒã®å»è¬çµæç©ã
- åèšè³Šåœ¢å€ããåèšå»è¬çµæç©ã®çŽïŒïŒ ïœïŒïœïœçŽïŒïŒ ïœïŒïœãæ§æãããè«æ±é ïŒïœïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšè³Šåœ¢å€ããåèšå»è¬çµæç©ã®çŽïŒïŒ ïœïŒïœãæ§æãããè«æ±é ïŒïœïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšè³Šåœ¢å€ã®åèšå¥åã®ãã¡ã€ã³ããåèšè¡šé¢äžã«ãããŠãåèšè³Šåœ¢å€ã®ïŒã€ä»¥äžã®äžé£ç¶ãã¡ã€ã³ãå«ããè«æ±é ïŒïœïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšè³Šåœ¢å€ã®åèšå¥åã®ãã¡ã€ã³ããåèšè³Šåœ¢å€ã®é£æ¥ããé£ç¶å±€ãå«ããè«æ±é ïŒïœïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšè³Šåœ¢å€ã氎溶æ§ã§ãããè«æ±é ïŒïœïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšè³Šåœ¢å€ãç³ã¢ã«ã³ãŒã«ãŸãã¯ã¢ããé žã§ãããè«æ±é ïŒïœïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšè³Šåœ¢å€ããã³ãããŒã«ãŸãã¯ãã€ã·ã³ã§ãããè«æ±é ïŒã«èšèŒã®å»è¬çµæç©ã
- åèšè³Šåœ¢å€ããåèšå»è¬çµæç©äžã«ãããã¡ã€ã³ãšããŠååšãããè«æ±é ïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšè³Šåœ¢å€ã®åèšãããã¡ã€ã³ããçŽïŒïŒïœïœïœçŽïŒïŒïŒïœïœã®å€§ãããæãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- çŽïŒïŒïŒïœçŽïŒïŒïŒÎŒïœã®ç©ºæ°åååŠç質éäžå€®ç²ååŸãæãããè«æ±é ïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšæ²»çè¬ããæçå€ãæçèå€ã粟ç¥ç¥çµçšå€ãäŸãã°é®çå€ãæèã¬ãã«ãå€åãããè¬å€ãäŸãã°éº»é è¬ãŸãã¯ç¡ç è¬ãéã¹ããã€ãæ§æççè¬ïŒïŒ®ïŒ³ïŒ¡ïŒ©ïŒ€ïŒ³ïŒãé§è«è¬ãããŒã¿ã¢ãŽãã¹ããæãããè¬ãæçå¿çè¬ãæäžæŽèè¬ãæåæ¯è¬ãæèè¬ãæè¯æ§åç«è ºè¥å€§è¬ãæååºè¬ãæãã€è¬ãæç³å°¿ç è¬ãé®åè¬ãæãŠãããè¬ãæç颚è¬ãæé«è¡å§è¬ãæççå€ãæãã©ãªã¢å€ãæçé çè¬ãæã ã¹ã«ãªã³å€ãæè «çè¬ãæè¥æºè¬ãæ骚ç²é¬çè¬ãæããŒãã³ãœã³ç è¬ãæå¢æ®å€ãæåè«è¬ãæç²ç¶è ºå€ãé®å³è¬ãæ尿倱çŠè¬ãæãŠã€ã«ã¹è¬ãæäžå®è¬ãé£æ¬²æå¶å€ãããŒã¿ãããã«ãŒãå¿èå€åå€ãååŠçæ³è¬ãèªç¥å¢åŒ·è¬ãé¿åŠè¬ãã³ã«ãã³ã¹ããã€ããïœïœïŒïŒé»å®³å€ãå©å°¿è¬ãåèµ·äžå šæ¹åè¬ãå»ç°è¬ãèè žè¬ããã¹ã¿ãã³å容äœæ®æè¬ãå ç«æå¶è¬ãè§è³ªæº¶è§£è¬ãè質調ç¯è¬ããã€ã³ããªãšã³é»å®³å€ããã¯ãã©ã€ããçåŒç·©è¬ãç¥çµé®æè¬ãæ é€å€ããªããªã€ãé®çå€ããããã¢ãŒãŒé»å®³å€ãããã³é®éè¬ãå«ã矀ããéžæããããè«æ±é ïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšæ²»çè¬ãæçèå€ã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- åèšæçèå€ãããªã³ããŸãŒã«ã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- ïŒçš®ä»¥äžã®è¿œå ã®è³Šåœ¢å€ãããã«å«ããè«æ±é ïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- ïŒçš®ä»¥äžã®è¿œå ã®æ²»çè¬ãããã«å«ããè«æ±é ïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- çµå£æäžãèèªå æäžãåèå æäžãé¢ç¯å æäžãé èå æäžãç®å æäžãç å·£å æäžãçèå æäžã錻è å æäžãçŒå æäžãå¿èå æäžãè ¹è å æäžãèžèå æäžãåç«è ºå æäžãçŽè žå æäžãé«è å æäžãæ°ç®¡å æäžãè «çå æäžãè垯å æäžãè£å æäžãéèå æäžãèè±å æäžãç¡åäœå æäžããªããœãŒã ã§ã®æäžãéšåçæäžãç²èæäžãéçµå£æäžãçŽè žæäžãçµèäžæäžãç®äžæäžãèäžæäžãå±ææäžãçµç®æäžãè£æäžãã¯ãªãŒã 圢æ ã§ã®æäžãè質çµæç©ã®åœ¢æ ã§ã®æäžãã«ããŒãã«ã«ããæäžãæŽæµã«ããæäžãæç¶æ³šå ¥ã«ããæäžãæ³šå ¥ã«ããæäžãåžå ¥ã«ããæäžã泚å°ã«ããæäžãå±æééã«ããæäžããŸãã¯å±æçæµã«ããæäžã®ããã«è£œå€åãããŠãããè«æ±é ïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åžå ¥ã«ããæäžã®ããã«è£œå€åãããŠãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- åžå ¥åšã§äœ¿çšããããã«è£œå€åãããŠãããè«æ±é ïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšåžå ¥åšããåºå®çšéã®çµã¿åããåžå ¥åšãååçšéã®ä¹Ÿç¥ç²æ«åžå ¥åšãè€æ°çšéã®ä¹Ÿç¥ç²æ«åžå ¥åšãè€æ°åäœçšéã®ä¹Ÿç¥ç²æ«åžå ¥åšãå®éåžå ¥åšããŸãã¯å å§å®éåžå ¥åšã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- åèšåžå ¥åšãã«ãã»ã«ããŒã¹ã®åžå ¥åšã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- åèšåžå ¥åšãäœæµæåžå ¥åšã§ãããè«æ±é ïŒïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšåžå ¥åšãé«æµæåžå ¥åšã§ãããè«æ±é ïŒïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšåžå ¥åšããçŽïŒïŒïŒ¬ïŒåïœçŽïŒïŒïŒïŒ¬ïŒåã®æµéã§äœ¿çšããããè«æ±é ïŒïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšåžå ¥åšãçŽïŒïŒïŒïœïœïœçŽïŒïŒïœïœã®è² è·çšéãæãããè«æ±é ïŒïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åžå ¥åšããé£ç¶çã«è² è·ãããïŒã€ä»¥äžã®åäœçšéãããïŒã€ã®ãŸãã¯äžé£ã®çšéãééããããã«æ§æãããŠãããè«æ±é ïŒïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- èºã®çŸæ£ãŸãã¯é害ãæ²»çãŸãã¯äºé²ããããã®ãè«æ±é ïŒïœïŒïŒã®ããããäžé ã«èšèŒã®å»è¬çµæç©ã
- åèšèºã®çŸæ£ãŸãã¯é害ãææçã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- åèšææçãçèææçã§ãããè«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ã
- ïŒïŒ¡ïŒããªã³ããŸãŒã«ãããã³
ïŒïŒ¢ïŒå»è¬çµæç©ã®çŽïŒïŒééïŒ æªæºãæ§æãã賊圢å€ã§ãã£ãŠããã³ãããŒã«ãŸãã¯ãã€ã·ã³ã§ããã賊圢å€
ãå«ããè«æ±é ïŒã«èšèŒã®å»è¬çµæç©ã§ãã£ãŠã
åèšå»è¬çµæç©ã¯ãããªã³ããŸãŒã«ã®ããç²åãå«ãããåéäœãšããŠè£œå€åãããŠãããããªã³ããŸãŒã«ã®åèšããç²åã®è¡šé¢ã¯ãåèšè³Šåœ¢å€ã®å¥åã®ãã¡ã€ã³ãå«ã¿ãåèšè³Šåœ¢å€ã®åèšå¥åã®ãã¡ã€ã³ã¯ããªã³ããŸãŒã«ã®åèšããç²åéã®æ¥è§Šé¢ç©ãæžå°ãããã
åèšå»è¬çµæç©ã
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862702674P | 2018-07-24 | 2018-07-24 | |
US62/702,674 | 2018-07-24 | ||
PCT/US2019/043202 WO2020023614A1 (en) | 2018-07-24 | 2019-07-24 | Compositions of surface-modified therapeutically active particles by ultra-rapid freezing |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021530551A JP2021530551A (ja) | 2021-11-11 |
JPWO2020023614A5 true JPWO2020023614A5 (ja) | 2022-08-01 |
Family
ID=69181152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021503813A Pending JP2021530551A (ja) | 2018-07-24 | 2019-07-24 | è¶ é«éåçµã«ããè¡šé¢æ¹è³ªãããæ²»ç掻æ§ç²åã®çµæç© |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210338671A1 (ja) |
EP (1) | EP3827260A4 (ja) |
JP (1) | JP2021530551A (ja) |
KR (1) | KR20210038583A (ja) |
CN (1) | CN112673257A (ja) |
AU (1) | AU2019311086A1 (ja) |
BR (1) | BR112021001290A2 (ja) |
CA (1) | CA3106618A1 (ja) |
EA (1) | EA202190331A1 (ja) |
IL (1) | IL280342A (ja) |
MX (1) | MX2021000796A (ja) |
WO (1) | WO2020023614A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014186754A2 (en) | 2013-05-16 | 2014-11-20 | Board Of Regents The University Of Texas System | Dry solid aluminum adjuvant-containing vaccines and related methods thereof |
WO2019118393A1 (en) | 2017-12-11 | 2019-06-20 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
CN113398079B (zh) * | 2020-03-16 | 2024-01-19 | é²åå¶è¯éå¢è¡ä»œæéå ¬åž | äžç§æ³šå°çšæ°èŸŸæ滚å»å¹²ç² |
BR112023003114A2 (pt) * | 2020-09-03 | 2023-04-04 | Philip Morris Products Sa | Composições em pó ativas de baixa higroscopicidade liofilizadas |
US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
US20220313611A1 (en) * | 2021-03-12 | 2022-10-06 | Board Of Regents, The University Of Texas System | Methods to prepare dry powders using suspension based thin film freezing |
US12015755B2 (en) | 2021-03-25 | 2024-06-18 | Korea Advanced Institute Of Science And Technology | Real-time omnidirectional stereo matching method using multi-view fisheye lenses and system thereof |
CN113484469B (zh) * | 2021-06-30 | 2022-11-18 | äžåœç§åŠé¢éæµ·çæ¹ç 究æ | æ°Žåçäœç³»çžååšèœææ纳米尺床çžå犻çåäœè¡šåŸæ¹æ³ |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
WO2007011396A2 (en) * | 2004-10-29 | 2007-01-25 | President And Fellows Of Harvard College | Particles for treatment of pulmonary infection |
EP1954246A4 (en) * | 2005-11-11 | 2012-01-18 | Biolab Sanus Farmaceutica Ltda | SOLID PHARMACEUTICAL COMPOSITION WITH AGGLOMERATE NANOTEILES AND MANUFACTURING METHOD THEREFOR |
US20120269721A1 (en) * | 2009-10-12 | 2012-10-25 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
AU2015393953B2 (en) * | 2015-05-01 | 2021-09-02 | Board Of Regents, The University Of Texas System | Multidrug brittle matrix compositions |
-
2019
- 2019-07-24 EP EP19840589.6A patent/EP3827260A4/en active Pending
- 2019-07-24 JP JP2021503813A patent/JP2021530551A/ja active Pending
- 2019-07-24 CN CN201980055623.XA patent/CN112673257A/zh active Pending
- 2019-07-24 CA CA3106618A patent/CA3106618A1/en active Pending
- 2019-07-24 MX MX2021000796A patent/MX2021000796A/es unknown
- 2019-07-24 EA EA202190331A patent/EA202190331A1/ru unknown
- 2019-07-24 BR BR112021001290-7A patent/BR112021001290A2/pt unknown
- 2019-07-24 AU AU2019311086A patent/AU2019311086A1/en active Pending
- 2019-07-24 WO PCT/US2019/043202 patent/WO2020023614A1/en unknown
- 2019-07-24 KR KR1020217005060A patent/KR20210038583A/ko unknown
- 2019-07-24 US US17/262,313 patent/US20210338671A1/en active Pending
-
2021
- 2021-01-21 IL IL280342A patent/IL280342A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2691033T3 (es) | Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mÃnimo el perfil de los efectos secundarios | |
ES2387749T3 (es) | Aerosoles que comprenden fármacos nanoparticulados | |
Mittal et al. | Insights into direct nose to brain delivery: current status and future perspective | |
EP0386232B1 (en) | Nasal administration of benzodiazepine hypnotics | |
JPWO2020023614A5 (ja) | ||
US20150342872A1 (en) | Use of Paclitaxel Particles | |
ES2953878T3 (es) | Composición que comprende al menos dos polvos secos obtenidos mediante secado por aspersión para aumentar la estabilidad de la formulación | |
JP2012526843A5 (ja) | ||
ES2582287B1 (es) | Procedimiento de obtención y composición farmacéutica de nanopartÃculas polimericas para el tratamiento de dolor neuropático producido por compresión nerviosa periférica | |
ES2896971T3 (es) | Formas de administración de hormona del crecimiento de acción prolongada | |
JP2017048250A5 (ja) | ||
Chellappan et al. | Protein and peptide delivery to lungs by using advanced targeted drug delivery | |
TWI494133B (zh) | éçµçšç²æ« | |
ES2291618T3 (es) | Composicion farmaceutica a base de un agente inhibidor de la pde4 o de la pde3/4 y de un agente antagonista de receptores de histamina. | |
CN107913261A (zh) | äžç§è¥¿ç»Žæ¥åžé å¹²ç²åžå ¥ååå ¶å¶å€æ¹æ³ | |
Garg et al. | Mucoadhesive drug delivery system in chronic respiratory diseases | |
TWI296928B (en) | Medicaments comprising betamimetics and a novel anticholinergic | |
WO2017206940A1 (en) | Metronomic oral gemcitabine for cancer therapy | |
Mardani et al. | Preparation and characterization of Celecoxib agglomerated nanocrystals and dry powder inhalation formulations to improve its aerosolization performance | |
Abdullah et al. | A OVERVIEW OF NASAL TO BRAIN DRUG DELIVERY | |
CN111053771A (zh) | çšäºæ²»çé£éé³ç¶ç»èççå¹åç±»ååç©æå ¶è¯åŠäžå¯æ¥åçç | |
JPH07508998A (ja) | æãŠã€ã«ã¹å€ã®çµã¿åãã | |
Shaikh Naziya et al. | AUTOMATED DRUG DISPENSING SYSTEM AND DEVICES | |
CN102058565A (zh) | äžç§æ°åè°å²çŽ åžå ¥ç²éŸååå ¶å¶å€æ¹æ³ | |
EP1655027A1 (en) | 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension and migraine |